

## Special Issue

# Ovarian Cancer in the Age of Precision Medicine

### Message from the Guest Editor

Ovarian cancer remains the most fatal gynecologic malignancy, with no effective screening modalities or diagnostic tests. This Special Issue will focus on the progress, challenges, and promise of omics to enable precision medicine for individuals with all types of ovarian cancer and how advances in precision medicine along the entire care continuum are needed to improve patient outcomes. In this Special Issue, research areas may include (but are not limited to) the following:

- New samples, technologies, and/or approaches for early detection, most notably for high-grade serous ovarian/tubal/peritoneal cancer;
- Targeted prevention strategies based on lifetime risk of ovarian cancer;
- Novel precision treatments for less common types of ovarian cancer;
- Understanding and overcoming resistance to targeted treatments;
- Using omics to increase the efficacy of immune-based treatments in ovarian cancer;
- Patient engagement in basic, preclinical, and clinical research investigating precision medicine strategies;
- Novel approaches for personalized survivorship.

I look forward to receiving your contributions.

---

### Guest Editor

Dr. Alicia A. Tone

Ovarian Cancer Canada, Toronto, ON M5A 1E3, Canada

---

### Deadline for manuscript submissions

closed (31 March 2025)



## Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/si/175718](https://mdpi.com/si/175718)

*Current Oncology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/  
currentoncol](https://mdpi.com/journal/currentoncol)







# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/journal/  
currentcol](https://mdpi.com/journal/currentcol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)